Mesa Laboratories (MLAB) Financials

$109.85 -1.17 (-1.05%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$109.79 -0.06 (-0.05%)

As of 05/23/2025 04:04 PM Eastern

Annual Income Statements for Mesa Laboratories

This table shows Mesa Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	3/31/2024	3/31/2023	3/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-254	0.93	1.87
Consolidated Net Income / (Loss)	-254	0.93	1.87
Net Income / (Loss) Continuing Operations	-254	0.93	1.87
Total Pre-Tax Income	-276	-0.39	3.57
Total Operating Income	-272	3.32	4.70
Total Gross Profit	133	134	109
Total Revenue	216	219	184
Operating Revenue	216	219	184
Total Cost of Revenue	83	85	75
Operating Cost of Revenue	83	85	75
Total Operating Expenses	405	130	104
Selling, General & Admin Expense	111	110	89
Research & Development Expense	19	20	16
Impairment Charge	275	0.00	0.00
Total Other Income / (Expense), net	-3.57	-3.71	-1.13
Interest Expense	5.70	4.77	3.89
Other Income / (Expense), net	2.12	1.06	2.76
Income Tax Expense	-21	-1.32	1.70
Basic Earnings per Share	($47.20)	$0.17	$0.36
Weighted Average Basic Shares Outstanding	5.39M	5.32M	5.21M
Diluted Earnings per Share	($47.20)	$0.17	$0.35
Weighted Average Diluted Shares Outstanding	5.39M	5.36M	5.34M
Weighted Average Basic & Diluted Shares Outstanding	5.41M	5.37M	5.27M
Cash Dividends to Common per Share	$0.64	$0.64	$0.64

This table shows Mesa Laboratories' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022	6/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-1.68	3.43	3.39	-255	2.12	-1.23	-0.55	0.61	0.45	1.31	-1.44
Consolidated Net Income / (Loss)	-1.68	3.43	3.39	-255	2.12	-1.23	-0.55	0.61	0.45	1.31	-1.44
Net Income / (Loss) Continuing Operations	-1.68	3.43	3.39	-255	2.12	-1.23	-0.55	0.61	0.45	1.31	-1.44
Total Pre-Tax Income	-2.22	3.81	3.91	-275	1.95	-1.33	-0.94	-0.28	1.92	3.38	-5.41
Total Operating Income	5.78	3.51	5.58	-271	-0.07	-0.06	-0.66	0.52	3.40	4.00	-4.59
Total Gross Profit	40	35	37	37	33	32	31	33	33	36	31
Total Revenue	63	58	58	59	53	53	51	56	54	59	50
Operating Revenue	63	58	58	59	53	53	51	56	54	59	50
Total Cost of Revenue	23	22	21	22	20	21	19	22	22	22	19
Operating Cost of Revenue	23	22	21	22	20	21	19	22	22	22	19
Total Operating Expenses	34	32	32	308	33	32	32	33	29	32	36
Selling, General & Admin Expense	29	27	27	28	29	27	27	28	25	27	30
Research & Development Expense	5.05	4.63	4.74	5.20	4.29	4.99	4.81	5.00	4.80	4.99	5.70
Total Other Income / (Expense), net	-8.00	0.30	-1.68	-4.05	2.01	-1.27	-0.27	-0.79	-1.49	-0.61	-0.82
Interest Expense	2.84	3.02	-0.36	1.89	1.86	0.91	1.05	1.38	1.16	1.21	1.01
Other Income / (Expense), net	-5.15	3.32	-2.03	-2.16	3.87	-0.36	0.78	0.59	-0.32	0.60	0.20
Income Tax Expense	-0.54	0.38	0.52	-21	-0.17	-0.10	-0.39	-0.89	1.47	2.08	-3.97
Basic Earnings per Share	($0.31)	$0.63	$0.63	($47.26)	$0.39	($0.23)	($0.10)	$0.11	$0.08	$0.25	($0.27)
Weighted Average Basic Shares Outstanding	5.43M	5.41M	5.40M	5.39M	5.39M	5.39M	5.37M	5.32M	5.34M	5.32M	5.27M
Diluted Earnings per Share	($0.31)	$0.63	$0.62	($47.26)	$0.39	($0.23)	($0.10)	$0.12	$0.08	$0.24	($0.27)
Weighted Average Diluted Shares Outstanding	5.43M	5.47M	5.42M	5.39M	5.40M	5.39M	5.37M	5.36M	5.36M	5.36M	5.27M
Weighted Average Basic & Diluted Shares Outstanding	5.43M	5.43M	5.41M	5.41M	5.39M	5.39M	5.38M	5.37M	5.35M	5.34M	5.32M
Cash Dividends to Common per Share	$0.16	$0.16	$0.16	$0.16	$0.16	$0.16	$0.16	$0.16	$0.16	$0.16	$0.16

This table details how cash moves in and out of Mesa Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	3/31/2024	3/31/2023	3/31/2022
Net Change in Cash & Equivalents	-4.70	-16	-215
Net Cash From Operating Activities	44	28	39
Net Cash From Continuing Operating Activities	44	28	39
Net Income / (Loss) Continuing Operations	-254	0.93	1.87
Consolidated Net Income / (Loss)	-254	0.93	1.87
Depreciation Expense	4.23	4.31	3.26
Amortization Expense	29	29	29
Non-Cash Adjustments To Reconcile Net Income	288	15	12
Changes in Operating Assets and Liabilities, net	-22	-21	-7.06
Net Cash From Investing Activities	-81	-9.49	-305
Net Cash From Continuing Investing Activities	-81	-9.49	-305
Purchase of Property, Plant & Equipment	-2.57	-4.54	-4.43
Acquisitions	-79	-4.95	-301
Net Cash From Financing Activities	33	-33	53
Net Cash From Continuing Financing Activities	33	-33	53
Repayment of Debt	-34	-36	-21
Payment of Dividends	-3.45	-3.41	-3.34
Issuance of Debt	71	0.00	70
Other Financing Activities, net	-0.37	6.08	7.15
Other Net Changes in Cash	-0.36	-1.60	-1.09
Cash Interest Paid	4.65	3.49	2.76
Cash Income Taxes Paid	4.59	1.36	3.05

This table details how cash moves in and out of Mesa Laboratories' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022	6/30/2022
Net Change in Cash & Equivalents	6.62	-4.14	0.26	-0.01	-7.39	3.24	-0.53	6.81	-6.28	-11	-5.60
Net Cash From Operating Activities	18	5.27	10	13	12	9.78	9.94	13	7.72	11	-2.81
Net Cash From Continuing Operating Activities	18	5.27	10	13	12	9.78	9.94	13	7.72	11	-2.81
Net Income / (Loss) Continuing Operations	-1.68	3.43	3.39	-255	2.12	-1.23	-0.55	0.61	0.45	1.31	-1.44
Consolidated Net Income / (Loss)	-1.68	3.43	3.39	-255	2.12	-1.23	-0.55	0.61	0.45	1.31	-1.44
Depreciation Expense	1.11	1.52	1.40	1.33	1.07	0.91	0.91	1.12	-13	8.06	8.13
Amortization Expense	4.39	5.00	4.84	6.19	7.98	7.19	7.22	7.25	-	-	-
Non-Cash Adjustments To Reconcile Net Income	11	1.33	1.14	280	0.47	4.27	3.48	4.11	3.71	3.05	3.66
Changes in Operating Assets and Liabilities, net	3.56	-6.01	-0.34	-20	-0.10	-1.36	-1.13	-0.56	-5.02	-1.86	-13
Net Cash From Investing Activities	-0.81	-1.79	-0.89	0.43	-81	-0.63	-0.27	-1.03	-6.60	-1.64	-0.23
Net Cash From Continuing Investing Activities	-0.81	-1.79	-0.89	0.43	-81	-0.63	-0.27	-1.03	-6.60	-1.64	-0.23
Purchase of Property, Plant & Equipment	-0.81	-1.79	-0.89	-0.54	-1.13	-0.63	-0.27	-1.03	-1.65	-1.64	-0.23
Net Cash From Financing Activities	-11	-8.61	-9.11	-13	61	-5.56	-9.52	-4.39	-8.88	-19	-1.41
Net Cash From Continuing Financing Activities	-11	-8.61	-9.11	-13	61	-5.56	-9.52	-4.39	-8.88	-19	-1.41
Repayment of Debt	-9.73	-7.74	-82	-12	-9.29	-4.70	-8.66	-6.00	-8.00	-20	-2.00
Payment of Dividends	-0.87	-0.87	-0.86	-0.86	-0.86	-0.86	-0.86	-0.86	-0.86	-0.85	-0.84
Effect of Exchange Rate Changes	-0.41	0.99	-0.18	-	-	-	-0.68	-	-	-1.64	-1.16

This table presents Mesa Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	3/31/2024	3/31/2023	3/31/2022
Total Assets	447	662	707
Total Current Assets	109	119	124
Cash & Equivalents	28	33	49
Accounts Receivable	39	43	41
Inventories, net	33	35	25
Prepaid Expenses	9.41	8.87	9.14
Plant, Property, & Equipment, net	32	28	29
Total Noncurrent Assets	306	515	554
Goodwill	180	286	291
Intangible Assets	114	217	250
Noncurrent Deferred & Refundable Income Taxes	1.29	1.08	1.32
Other Noncurrent Operating Assets	11	10	12
Total Liabilities & Shareholders' Equity	447	662	707
Total Liabilities	301	268	314
Total Current Liabilities	44	43	48
Short-Term Debt	0.00	-	-
Accounts Payable	6.04	6.13	7.90
Accrued Expenses	13	12	12
Current Deferred Revenue	15	16	14
Current Employee Benefit Liabilities	9.94	9.43	15
Total Noncurrent Liabilities	257	225	266
Long-Term Debt	222	183	218
Noncurrent Deferred & Payable Income Tax Liabilities	20	34	39
Other Noncurrent Operating Liabilities	16	7.69	7.92
Total Equity & Noncontrolling Interests	145	393	394
Total Preferred & Common Equity	145	393	394
Total Common Equity	145	393	394
Common Stock	344	332	313
Retained Earnings	-183	74	77
Accumulated Other Comprehensive Income / (Loss)	-15	-13	3.67

This table presents Mesa Laboratories' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023
Period end date	12/31/2024	9/30/2024	6/30/2024	12/31/2023	9/30/2023	6/30/2023	12/31/2022	9/30/2022	6/30/2022
Total Assets	437	454	440	742	637	643	663	656	686
Total Current Assets	111	108	107	118	118	115	114	116	128
Cash & Equivalents	31	24	28	28	36	32	26	32	44
Accounts Receivable	39	40	36	36	36	36	42	42	42
Inventories, net	28	30	32	36	33	36	34	28	27
Prepaid Expenses	13	14	11	18	13	11	12	14	16
Plant, Property, & Equipment, net	32	32	31	32	29	28	28	28	28
Total Noncurrent Assets	295	314	302	592	491	500	521	512	530
Goodwill	177	184	180	346	283	284	286	278	284
Intangible Assets	98	109	109	233	198	205	223	222	235
Noncurrent Deferred & Refundable Income Taxes	1.24	1.33	1.28	1.09	1.05	1.08	0.71	0.65	0.69
Other Noncurrent Operating Assets	18	20	12	12	8.95	9.62	11	11	10
Total Liabilities & Shareholders' Equity	437	454	440	742	637	643	663	656	686
Total Liabilities	282	293	290	339	249	255	276	282	305
Total Current Liabilities	156	153	55	44	40	39	42	42	44
Short-Term Debt	101	101	3.75	-	-	-	-	-	-
Accounts Payable	4.09	5.99	5.66	4.55	4.81	5.59	6.29	7.74	7.56
Accrued Expenses	22	23	22	16	12	11	13	12	12
Current Deferred Revenue	15	14	15	14	14	15	15	14	15
Current Employee Benefit Liabilities	14	9.19	8.34	9.38	8.35	7.27	8.13	7.48	9.40
Total Noncurrent Liabilities	126	139	235	295	210	216	234	240	261
Long-Term Debt	95	104	208	233	171	176	189	197	217
Noncurrent Deferred & Payable Income Tax Liabilities	19	21	20	44	33	34	37	37	37
Other Noncurrent Operating Liabilities	12	15	6.58	17	5.44	6.76	8.17	6.83	7.34
Total Equity & Noncontrolling Interests	155	161	151	403	388	388	387	374	380
Total Preferred & Common Equity	155	161	151	403	388	388	387	374	380
Total Common Equity	155	161	151	403	388	388	387	374	380
Common Stock	353	350	346	341	338	334	327	325	318
Retained Earnings	-181	-178	-181	72	71	73	74	75	74
Accumulated Other Comprehensive Income / (Loss)	-17	-9.67	-14	-9.84	-21	-19	-14	-26	-12

This table displays calculated financial ratios and metrics derived from Mesa Laboratories' official financial filings.

Metric	2024	2023	2022
Period end date	3/31/2024	3/31/2023	3/31/2022
Growth Metrics	-	-	-
Revenue Growth	-1.32%	18.85%	37.63%
EBITDA Growth	-732.14%	-6.19%	45.15%
EBIT Growth	-6,261.86%	-41.27%	-27.77%
NOPAT Growth	-8,295.03%	-5.59%	-85.99%
Net Income Growth	-27,438.28%	-50.29%	-42.85%
EPS Growth	-27,864.71%	-51.43%	-45.31%
Operating Cash Flow Growth	57.71%	-28.66%	5.80%
Free Cash Flow Firm Growth	-31.87%	107.82%	-3,325.63%
Invested Capital Growth	-37.69%	-3.37%	95.40%
Revenue Q/Q Growth	1.56%	-1.48%	12.80%
EBITDA Q/Q Growth	-720.16%	-6.12%	0.19%
EBIT Q/Q Growth	-5,973.61%	-0.66%	-44.50%
NOPAT Q/Q Growth	-99,197.45%	23.28%	-69.63%
Net Income Q/Q Growth	-26,919.20%	163.48%	-75.30%
EPS Q/Q Growth	-26,322.22%	158.62%	-75.86%
Operating Cash Flow Q/Q Growth	0.83%	12.99%	-9.71%
Free Cash Flow Firm Q/Q Growth	125.13%	-16.46%	-3.82%
Invested Capital Q/Q Growth	-44.24%	-1.15%	-1.91%
Profitability Metrics	-	-	-
Gross Margin	61.64%	61.02%	59.18%
EBITDA Margin	-109.70%	17.12%	21.69%
Operating Margin	-125.85%	1.52%	2.55%
EBIT Margin	-124.87%	2.00%	4.05%
Profit (Net Income) Margin	-117.60%	0.42%	1.02%
Tax Burden Percent	92.24%	-239.07%	52.35%
Interest Burden Percent	102.11%	-8.88%	47.92%
Effective Tax Rate	0.00%	0.00%	47.65%
Return on Invested Capital (ROIC)	-43.15%	0.42%	0.58%
ROIC Less NNEP Spread (ROIC-NNEP)	-80.26%	-0.45%	-1.74%
Return on Net Nonoperating Assets (RNNOA)	-51.21%	-0.18%	-0.11%
Return on Equity (ROE)	-94.36%	0.24%	0.47%
Cash Return on Invested Capital (CROIC)	3.29%	3.85%	-64.01%
Operating Return on Assets (OROA)	-48.70%	0.64%	1.14%
Return on Assets (ROA)	-45.87%	0.14%	0.29%
Return on Common Equity (ROCE)	-94.36%	0.24%	0.47%
Return on Equity Simple (ROE_SIMPLE)	-174.87%	0.24%	0.48%
Net Operating Profit after Tax (NOPAT)	-190	2.32	2.46
NOPAT Margin	-88.10%	1.06%	1.34%
Net Nonoperating Expense Percent (NNEP)	37.11%	0.87%	2.32%
Cost of Revenue to Revenue	38.36%	38.98%	40.82%
SG&A Expenses to Revenue	51.57%	50.16%	48.08%
R&D to Revenue	8.93%	9.35%	8.55%
Operating Expenses to Revenue	187.49%	59.51%	56.63%
Earnings before Interest and Taxes (EBIT)	-270	4.38	7.46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-237	38	40
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.07	2.36	3.36
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.73	4.23	7.18
Price to Earnings (P/E)	0.00	997.39	707.10
Dividend Yield	0.58%	0.37%	0.25%
Earnings Yield	0.00%	0.10%	0.14%
Enterprise Value to Invested Capital (EV/IC)	2.32	1.98	2.65
Enterprise Value to Revenue (EV/Rev)	3.63	4.92	8.09
Enterprise Value to EBITDA (EV/EBITDA)	0.00	28.73	37.31
Enterprise Value to EBIT (EV/EBIT)	0.00	246.05	200.03
Enterprise Value to NOPAT (EV/NOPAT)	0.00	463.83	606.13
Enterprise Value to Operating Cash Flow (EV/OCF)	17.78	38.52	38.04
Enterprise Value to Free Cash Flow (EV/FCFF)	54.06	50.60	0.00
Leverage & Solvency	-	-	-
Debt to Equity	1.52	0.47	0.55
Long-Term Debt to Equity	1.52	0.47	0.55
Financial Leverage	0.64	0.41	0.06
Leverage Ratio	2.06	1.74	1.64
Compound Leverage Factor	2.10	-0.15	0.78
Debt to Total Capital	60.39%	31.78%	35.67%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	60.39%	31.78%	35.67%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	39.61%	68.22%	64.33%
Debt to EBITDA	-0.93	4.89	5.46
Net Debt to EBITDA	-0.82	4.01	4.23
Long-Term Debt to EBITDA	-0.93	4.89	5.46
Debt to NOPAT	-1.16	78.86	88.71
Net Debt to NOPAT	-1.02	64.70	68.66
Long-Term Debt to NOPAT	-1.16	78.86	88.71
Altman Z-Score	-0.73	2.72	3.11
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	2.47	2.74	2.59
Quick Ratio	1.52	1.74	1.88
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	15	21	-272
Operating Cash Flow to CapEx	1,719.24%	615.82%	885.00%
Free Cash Flow to Firm to Interest Expense	2.55	4.47	-70.10
Operating Cash Flow to Interest Expense	7.75	5.87	10.10
Operating Cash Flow Less CapEx to Interest Expense	7.30	4.91	8.96
Efficiency Ratios	-	-	-
Asset Turnover	0.39	0.32	0.28
Accounts Receivable Turnover	5.30	5.23	5.67
Inventory Turnover	2.46	2.88	4.21
Fixed Asset Turnover	7.22	7.72	7.28
Accounts Payable Turnover	13.62	12.17	12.17
Days Sales Outstanding (DSO)	68.89	69.79	64.36
Days Inventory Outstanding (DIO)	148.13	126.63	86.79
Days Payable Outstanding (DPO)	26.79	29.99	30.00
Cash Conversion Cycle (CCC)	190.23	166.43	121.15
Capital & Investment Metrics	-	-	-
Invested Capital	339	544	563
Invested Capital Turnover	0.49	0.40	0.43
Increase / (Decrease) in Invested Capital	-205	-19	275
Enterprise Value (EV)	785	1,078	1,492
Market Capitalization	591	928	1,323
Book Value per Share	$26.95	$73.60	$75.07
Tangible Book Value per Share	($27.52)	($20.53)	($28.11)
Total Capital	367	577	612
Total Debt	222	183	218
Total Long-Term Debt	222	183	218
Net Debt	193	150	169
Capital Expenditures (CapEx)	2.57	4.54	4.43
Debt-free, Cash-free Net Working Capital (DFCFNWC)	37	43	27
Debt-free Net Working Capital (DFNWC)	65	76	76
Net Working Capital (NWC)	65	76	76
Net Nonoperating Expense (NNE)	64	1.39	0.59
Net Nonoperating Obligations (NNO)	193	150	169
Total Depreciation and Amortization (D&A)	33	33	33
Debt-free, Cash-free Net Working Capital to Revenue	17.03%	19.49%	14.60%
Debt-free Net Working Capital to Revenue	30.09%	34.52%	41.37%
Net Working Capital to Revenue	30.09%	34.52%	41.37%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($47.20)	$0.17	$0.36
Adjusted Weighted Average Basic Shares Outstanding	5.39M	5.32M	5.21M
Adjusted Diluted Earnings per Share	($47.20)	$0.17	$0.35
Adjusted Weighted Average Diluted Shares Outstanding	5.39M	5.36M	5.34M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	5.41M	5.37M	5.27M
Normalized Net Operating Profit after Tax (NOPAT)	1.72	2.32	2.46
Normalized NOPAT Margin	0.80%	1.06%	1.34%
Pre Tax Income Margin	-127.50%	-0.18%	1.94%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-47.38	0.92	1.92
NOPAT to Interest Expense	-33.43	0.49	0.63
EBIT Less CapEx to Interest Expense	-47.84	-0.03	0.78
NOPAT Less CapEx to Interest Expense	-33.88	-0.47	-0.51
Payout Ratios	-	-	-
Dividend Payout Ratio	-1.36%	366.24%	178.46%
Augmented Payout Ratio	-1.36%	366.24%	178.46%

This table displays calculated financial ratios and metrics derived from Mesa Laboratories' official financial filings.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022	6/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	17.52%	8.78%	14.86%	5.96%	-1.50%	-9.50%	0.38%	-5.58%	-0.75%	63.92%	44.48%
EBITDA Growth	-52.36%	73.94%	18.78%	-2,908.62%	229.61%	-39.33%	120.69%	-20.53%	-279.82%	31.32%	-45.57%
EBIT Growth	-83.56%	1,726.19%	3,098.20%	-24,890.93%	23.52%	-109.13%	102.52%	-2.56%	332.65%	-14.18%	-291.88%
NOPAT Growth	5,652.69%	7,611.01%	1,141.57%	-52,572.73%	-109.10%	-102.72%	85.55%	570.00%	145.54%	-55.18%	-173.19%
Net Income Growth	-179.21%	378.70%	717.12%	-41,766.61%	369.18%	-194.18%	61.82%	134.25%	121.89%	-64.89%	-172.08%
EPS Growth	-179.49%	373.91%	720.00%	-39,483.33%	387.50%	-195.83%	62.96%	135.29%	120.51%	-65.71%	-171.05%
Operating Cash Flow Growth	59.85%	-46.08%	4.97%	2.91%	49.46%	-7.40%	453.58%	34.58%	-51.45%	138.09%	-129.31%
Free Cash Flow Firm Growth	606.31%	1,067.24%	815.96%	-22.10%	-336.02%	106.38%	108.30%	107.04%	108.97%	-3,457.26%	-4,650.35%
Invested Capital Growth	-47.35%	-34.57%	-36.99%	-37.69%	10.46%	-2.93%	-4.05%	-3.37%	-4.12%	85.72%	89.49%
Revenue Q/Q Growth	8.66%	-0.58%	-1.25%	10.16%	0.58%	4.98%	-8.90%	2.40%	-7.60%	16.44%	-14.31%
EBITDA Q/Q Growth	-54.15%	36.34%	103.68%	-2,690.64%	67.42%	-6.90%	-12.92%	195.49%	-178.36%	238.68%	-68.64%
EBIT Q/Q Growth	-90.85%	92.39%	101.30%	-7,292.11%	1,005.24%	-478.38%	-89.94%	-64.17%	-33.06%	204.55%	-488.52%
NOPAT Q/Q Growth	28.23%	-34.84%	102.55%	-260,560.23%	-73.46%	90.96%	-228.43%	-54.81%	-48.06%	147.94%	-4,076.36%
Net Income Q/Q Growth	-148.89%	1.18%	101.33%	-12,131.33%	272.03%	-124.04%	-189.85%	35.48%	-65.47%	190.82%	19.39%
EPS Q/Q Growth	-149.21%	1.61%	101.31%	-12,217.95%	269.57%	-130.00%	-183.33%	50.00%	-66.67%	188.89%	20.59%
Operating Cash Flow Q/Q Growth	249.82%	-49.48%	-19.02%	11.69%	17.99%	-1.64%	-20.61%	62.21%	-26.89%	475.56%	-130.22%
Free Cash Flow Firm Q/Q Growth	58.63%	-8.57%	1,235.32%	126.14%	-465.70%	-28.26%	13.57%	-20.79%	109.88%	6.58%	3.77%
Invested Capital Q/Q Growth	-6.47%	2.27%	-1.29%	-44.24%	16.22%	-1.50%	-2.39%	-1.15%	2.13%	-2.64%	-1.70%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	63.26%	61.31%	64.03%	62.06%	62.47%	60.40%	61.57%	59.72%	60.36%	61.93%	62.12%
EBITDA Margin	9.74%	23.09%	16.84%	-451.45%	24.03%	14.44%	16.28%	17.03%	-18.26%	21.54%	7.40%
Operating Margin	9.20%	6.07%	9.59%	-460.55%	-0.13%	-0.11%	-1.31%	0.93%	6.27%	6.80%	-9.11%
EBIT Margin	0.99%	11.81%	6.10%	-464.22%	7.11%	-0.79%	0.22%	1.98%	5.67%	7.83%	-8.72%
Profit (Net Income) Margin	-2.67%	5.93%	5.82%	-432.20%	3.96%	-2.31%	-1.08%	1.10%	0.83%	2.22%	-2.85%
Tax Burden Percent	75.60%	89.93%	86.76%	92.46%	108.74%	92.83%	58.59%	-220.58%	23.54%	38.59%	26.57%
Interest Burden Percent	-354.72%	55.81%	110.00%	100.69%	51.18%	315.48%	-844.14%	-25.11%	62.25%	73.60%	123.06%
Effective Tax Rate	0.00%	10.07%	13.24%	0.00%	-8.74%	0.00%	0.00%	0.00%	76.46%	61.41%	0.00%
Return on Invested Capital (ROIC)	3.30%	2.88%	4.30%	-157.91%	-0.05%	-0.03%	-0.37%	0.26%	0.58%	1.41%	-3.01%
ROIC Less NNEP Spread (ROIC-NNEP)	0.20%	3.05%	3.41%	-195.54%	1.14%	-0.83%	-0.42%	0.41%	0.38%	0.55%	2.39%
Return on Net Nonoperating Assets (RNNOA)	0.13%	1.76%	2.07%	-124.77%	0.53%	-0.32%	-0.17%	0.17%	0.16%	0.04%	0.20%
Return on Equity (ROE)	3.43%	4.64%	6.38%	-282.68%	0.48%	-0.36%	-0.55%	0.43%	0.75%	1.45%	-2.81%
Cash Return on Invested Capital (CROIC)	23.33%	-0.65%	2.37%	3.29%	-9.97%	3.40%	4.73%	3.85%	4.54%	-60.55%	-62.32%
Operating Return on Assets (OROA)	0.40%	4.94%	2.52%	-181.05%	2.15%	-0.26%	0.07%	0.63%	1.82%	2.76%	-2.68%
Return on Assets (ROA)	-1.08%	2.48%	2.41%	-168.56%	1.20%	-0.76%	-0.36%	0.35%	0.27%	0.78%	-0.88%
Return on Common Equity (ROCE)	3.43%	4.64%	6.38%	-282.68%	0.48%	-0.36%	-0.55%	0.43%	0.75%	1.45%	-2.81%
Return on Equity Simple (ROE_SIMPLE)	-160.71%	-152.15%	-166.07%	0.00%	0.24%	-0.18%	0.47%	0.00%	-0.38%	-1.06%	-0.41%
Net Operating Profit after Tax (NOPAT)	4.05	3.15	4.84	-190	-0.07	-0.04	-0.46	0.36	0.80	1.54	-3.22
NOPAT Margin	6.44%	5.45%	8.32%	-322.39%	-0.14%	-0.08%	-0.92%	0.65%	1.48%	2.62%	-6.37%
Net Nonoperating Expense Percent (NNEP)	3.10%	-0.17%	0.89%	37.62%	-1.19%	0.79%	0.05%	-0.16%	0.21%	0.86%	-5.40%
Return On Investment Capital (ROIC_SIMPLE)	1.15%	-	-	-	-0.01%	-	-	-	-	-	-
Cost of Revenue to Revenue	36.74%	38.69%	35.97%	37.94%	37.53%	39.61%	38.43%	40.28%	39.64%	38.07%	37.88%
SG&A Expenses to Revenue	46.02%	47.23%	46.30%	47.71%	54.56%	51.12%	53.38%	49.79%	45.25%	46.64%	59.93%
R&D to Revenue	8.04%	8.01%	8.14%	8.83%	8.03%	9.39%	9.50%	9.00%	8.84%	8.49%	11.30%
Operating Expenses to Revenue	54.07%	55.24%	54.44%	522.61%	62.59%	60.51%	62.88%	58.79%	54.09%	55.13%	71.22%
Earnings before Interest and Taxes (EBIT)	0.63	6.83	3.55	-273	3.80	-0.42	0.11	1.10	3.08	4.60	-4.40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	6.12	13	9.79	-266	13	7.68	8.25	9.47	-9.92	13	3.74
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.61	4.35	3.11	4.07	1.39	1.45	1.77	2.36	2.27	1.98	2.80
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.01	3.08	2.10	2.73	2.64	2.63	3.13	4.23	3.96	3.33	5.32
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	592.62	0.00	377.12	997.39	0.00	0.00	0.00
Dividend Yield	0.49%	0.49%	0.74%	0.58%	0.61%	0.61%	0.50%	0.37%	0.39%	0.46%	0.32%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.17%	0.00%	0.27%	0.10%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.75	2.58	1.95	2.32	1.26	1.33	1.56	1.98	1.90	1.68	2.24
Enterprise Value to Revenue (EV/Rev)	3.71	3.87	2.92	3.63	3.60	3.26	3.78	4.92	4.69	4.07	6.19
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	20.05	0.00	138.58	28.73	26.10	85.44	162.87
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	166.79	180.14	93.26	246.05	236.49	100,734.97	1,608.13
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	311.86	256.88	463.83	553.24	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	18.73	22.01	14.64	17.78	17.51	17.46	20.35	38.52	42.11	27.52	46.10
Enterprise Value to Free Cash Flow (EV/FCFF)	8.14	0.00	63.66	54.06	0.00	38.67	32.32	50.60	40.90	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.26	1.27	1.41	1.52	0.58	0.44	0.45	0.47	0.49	0.53	0.57
Long-Term Debt to Equity	0.61	0.65	1.38	1.52	0.58	0.44	0.45	0.47	0.49	0.53	0.57
Financial Leverage	0.66	0.57	0.61	0.64	0.47	0.39	0.41	0.41	0.43	0.07	0.08
Leverage Ratio	2.11	1.99	2.01	2.06	1.78	1.70	1.73	1.74	1.77	1.64	1.67
Compound Leverage Factor	-7.49	1.11	2.21	2.07	0.91	5.35	-14.60	-0.44	1.10	1.20	2.05
Debt to Total Capital	55.77%	55.94%	58.47%	60.39%	36.63%	30.57%	31.16%	31.78%	32.81%	34.47%	36.28%
Short-Term Debt to Total Capital	28.76%	27.50%	1.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	27.01%	28.44%	57.44%	60.39%	36.63%	30.57%	31.16%	31.78%	32.81%	34.47%	36.28%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	44.23%	44.06%	41.53%	39.61%	63.37%	69.43%	68.84%	68.22%	67.19%	65.53%	63.72%
Debt to EBITDA	-0.83	-0.89	-0.90	-0.93	6.09	-27.63	29.33	4.89	4.73	18.55	28.53
Net Debt to EBITDA	-0.70	-0.79	-0.78	-0.82	5.35	-21.87	23.92	4.01	4.08	15.50	22.76
Long-Term Debt to EBITDA	-0.40	-0.45	-0.89	-0.93	6.09	-27.63	29.33	4.89	4.73	18.55	28.53
Debt to NOPAT	-1.09	-1.12	-1.14	-1.16	-1,214.62	76.34	54.38	78.86	100.28	-87.29	-102.63
Net Debt to NOPAT	-0.92	-0.98	-0.99	-1.02	-1,067.47	60.41	44.35	64.70	86.44	-72.93	-81.90
Long-Term Debt to NOPAT	-0.53	-0.57	-1.12	-1.16	-1,214.62	76.34	54.38	78.86	100.28	-87.29	-102.63
Altman Z-Score	1.37	1.32	1.07	-0.76	1.55	1.99	2.26	2.70	2.55	2.24	2.66
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.71	0.70	1.94	2.47	2.68	2.96	2.93	2.74	2.74	2.80	2.90
Quick Ratio	0.45	0.42	1.17	1.52	1.45	1.81	1.74	1.74	1.65	1.79	1.94
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	292	184	201	15	-58	16	22	19	24	-247	-265
Operating Cash Flow to CapEx	2,268.02%	294.80%	1,170.93%	2,408.04%	1,022.61%	1,541.96%	3,681.11%	1,220.18%	466.63%	644.11%	-1,249.33%
Free Cash Flow to Firm to Interest Expense	102.66	60.95	0.00	7.98	-31.05	17.41	20.96	14.01	21.01	-203.54	-260.85
Operating Cash Flow to Interest Expense	6.49	1.75	0.00	6.82	6.22	10.80	9.48	9.07	6.64	8.70	-2.77
Operating Cash Flow Less CapEx to Interest Expense	6.20	1.15	0.00	6.54	5.61	10.10	9.23	8.33	5.22	7.35	-2.99
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.40	0.42	0.41	0.39	0.30	0.33	0.33	0.32	0.32	0.35	0.31
Accounts Receivable Turnover	6.37	5.96	6.29	5.30	5.43	5.47	5.66	5.23	5.58	6.91	6.40
Inventory Turnover	2.77	2.74	2.51	2.46	2.38	2.77	2.75	2.88	3.02	4.55	4.19
Fixed Asset Turnover	7.50	7.53	7.54	7.22	7.09	7.52	7.84	7.72	7.61	8.80	8.00
Accounts Payable Turnover	20.54	15.88	15.01	13.62	15.31	13.46	13.04	12.17	12.29	14.97	14.07
Days Sales Outstanding (DSO)	57.32	61.19	58.05	68.89	67.23	66.74	64.45	69.79	65.40	52.79	56.99
Days Inventory Outstanding (DIO)	131.83	133.32	145.59	148.13	153.32	131.68	132.90	126.63	120.86	80.26	87.16
Days Payable Outstanding (DPO)	17.77	22.99	24.32	26.79	23.85	27.12	27.98	29.99	29.69	24.39	25.93
Cash Conversion Cycle (CCC)	171.37	171.52	179.32	190.23	196.70	171.30	169.36	166.43	156.57	108.67	118.23
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	320	342	335	339	608	523	531	544	550	539	553
Invested Capital Turnover	0.51	0.53	0.52	0.49	0.37	0.40	0.40	0.40	0.40	0.54	0.47
Increase / (Decrease) in Invested Capital	-288	-181	-196	-205	58	-16	-22	-19	-24	249	261
Enterprise Value (EV)	881	883	653	785	767	697	829	1,078	1,043	907	1,237
Market Capitalization	716	702	469	591	562	562	686	928	880	742	1,064
Book Value per Share	$28.58	$29.85	$27.87	$26.95	$74.74	$72.02	$72.20	$73.60	$72.55	$70.38	$72.22
Tangible Book Value per Share	($22.12)	($24.24)	($25.60)	($27.52)	($32.64)	($17.31)	($18.89)	($20.53)	($22.87)	($23.70)	($26.22)
Total Capital	351	366	363	367	636	558	563	577	576	571	597
Total Debt	196	205	212	222	233	171	176	183	189	197	217
Total Long-Term Debt	95	104	208	222	233	171	176	183	189	197	217
Net Debt	165	181	184	193	205	135	143	150	163	164	173
Capital Expenditures (CapEx)	0.81	1.79	0.89	0.54	1.13	0.63	0.27	1.03	1.65	1.64	0.23
Debt-free, Cash-free Net Working Capital (DFCFNWC)	25	31	27	37	46	42	43	43	46	42	40
Debt-free Net Working Capital (DFNWC)	56	56	56	65	74	78	76	76	73	75	84
Net Working Capital (NWC)	-45	-45	52	65	74	78	76	76	73	75	84
Net Nonoperating Expense (NNE)	5.72	-0.27	1.45	65	-2.19	1.19	0.08	-0.25	0.35	0.24	-1.78
Net Nonoperating Obligations (NNO)	165	181	184	193	205	135	143	150	163	164	173
Total Depreciation and Amortization (D&A)	5.50	6.52	6.24	7.52	9.05	8.10	8.13	8.37	-13	8.06	8.13
Debt-free, Cash-free Net Working Capital to Revenue	10.48%	13.66%	12.12%	17.03%	21.58%	19.76%	19.75%	19.49%	20.90%	19.02%	20.14%
Debt-free Net Working Capital to Revenue	23.50%	24.31%	24.84%	30.09%	34.84%	36.43%	34.52%	34.52%	32.63%	33.56%	42.03%
Net Working Capital to Revenue	-18.94%	-19.81%	23.17%	30.09%	34.84%	36.43%	34.52%	34.52%	32.63%	33.56%	42.03%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.31)	$0.63	$0.63	($47.26)	$0.39	($0.23)	($0.10)	$0.11	$0.08	$0.25	($0.27)
Adjusted Weighted Average Basic Shares Outstanding	5.43M	5.41M	5.40M	5.39M	5.39M	5.39M	5.37M	5.32M	5.34M	5.32M	5.27M
Adjusted Diluted Earnings per Share	($0.31)	$0.63	$0.62	($47.26)	$0.39	($0.23)	($0.10)	$0.12	$0.08	$0.24	($0.27)
Adjusted Weighted Average Diluted Shares Outstanding	5.43M	5.47M	5.42M	5.39M	5.40M	5.39M	5.37M	5.36M	5.36M	5.36M	5.27M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	5.43M	5.43M	5.41M	5.41M	5.39M	5.39M	5.38M	5.37M	5.35M	5.34M	5.32M
Normalized Net Operating Profit after Tax (NOPAT)	4.05	3.15	4.84	-190	-0.05	-0.04	-0.46	0.36	2.38	2.80	-3.22
Normalized NOPAT Margin	6.44%	5.45%	8.32%	-322.39%	-0.09%	-0.08%	-0.92%	0.65%	4.39%	4.76%	-6.37%
Pre Tax Income Margin	-3.53%	6.59%	6.71%	-467.43%	3.64%	-2.49%	-1.85%	-0.50%	3.53%	5.76%	-10.73%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.22	2.26	0.00	-144.83	2.05	-0.46	0.11	0.80	2.65	3.79	-4.34
NOPAT to Interest Expense	1.42	1.05	0.00	-100.58	-0.04	-0.05	-0.44	0.26	0.69	1.27	-3.17
EBIT Less CapEx to Interest Expense	-0.07	1.67	0.00	-145.12	1.44	-1.16	-0.15	0.06	1.23	2.44	-4.56
NOPAT Less CapEx to Interest Expense	1.14	0.45	0.00	-100.87	-0.65	-0.75	-0.70	-0.48	-0.73	-0.08	-3.39
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-1.39%	-1.41%	-1.38%	-1.36%	362.76%	-478.66%	188.13%	366.24%	-231.67%	-84.91%	-214.98%
Augmented Payout Ratio	-1.39%	-1.41%	-1.38%	-1.36%	362.76%	-478.66%	188.13%	366.24%	-231.67%	-84.91%	-214.98%

Frequently Asked Questions About Mesa Laboratories' Financials

When does Mesa Laboratories's fiscal year end?

According to the most recent income statement we have on file, Mesa Laboratories' financial year ends in March. Their financial year 2024 ended on March 31, 2024.

How has Mesa Laboratories' net income changed over the last 2 years?

Mesa Laboratories' net income appears to be on an upward trend, with a most recent value of -$254.25 million in 2024, falling from $1.87 million in 2022. The previous period was $930 thousand in 2023. Find out what analysts predict for Mesa Laboratories in the coming months.

What is Mesa Laboratories's operating income?

Mesa Laboratories's total operating income in 2024 was -$272.08 million, based on the following breakdown:

Total Gross Profit: $133.25 million
Total Operating Expenses: $405.33 million

How has Mesa Laboratories revenue changed over the last 2 years?

Over the last 2 years, Mesa Laboratories' total revenue changed from $184.34 million in 2022 to $216.19 million in 2024, a change of 17.3%.

How much debt does Mesa Laboratories have?

Mesa Laboratories' total liabilities were at $301.40 million at the end of 2024, a 12.3% increase from 2023, and a 3.9% decrease since 2022.

How much cash does Mesa Laboratories have?

In the past 2 years, Mesa Laboratories' cash and equivalents has ranged from $28.21 million in 2024 to $49.35 million in 2022, and is currently $28.21 million as of their latest financial filing in 2024.

How has Mesa Laboratories' book value per share changed over the last 2 years?

Over the last 2 years, Mesa Laboratories' book value per share changed from 75.07 in 2022 to 26.95 in 2024, a change of -64.1%.

Related Companies

This page (NASDAQ:MLAB) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mesa Laboratories (MLAB) Financials

Frequently Asked Questions About Mesa Laboratories' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mesa Laboratories (MLAB) Financials

Annual Income Statements for Mesa Laboratories

Quarterly Income Statements for Mesa Laboratories

Annual Cash Flow Statements for Mesa Laboratories

Quarterly Cash Flow Statements for Mesa Laboratories

Annual Balance Sheets for Mesa Laboratories

Quarterly Balance Sheets for Mesa Laboratories

Annual Metrics And Ratios for Mesa Laboratories

Quarterly Metrics And Ratios for Mesa Laboratories

Frequently Asked Questions About Mesa Laboratories' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools